p.90 抽出テキスト

EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am College Cardiol 2012;59:1598–1603. https://doi.org/10. 1016/j.jacc.2011.11.063 509. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, et al. Survival and hospitalization in heart failure patients with or without diabetes treated with β-blockers. J Cardiac Fail 2003;9:192–202. https://doi.org/10.1054/jcaf.2003.31 510. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159–167. https://doi.org/10. 1016/j.ahj.2004.05.056 511. Erdmann E, Philippe L, Patricia V, Hermann W. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469–479. https://doi.org/10.1016/S1388-9842(01)00174-X 512. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194–2199. https://doi.org/10.1161/01.CIR.0000035653.72855.BF 513. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- Alternative trial. Lancet 2003;362:772–776. https://doi.org/10.1016/S0140-6736(03) 14284-5 514. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374: 1840–1848. https://doi.org/10.1016/S0140-6736(09)61913-9 515. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am College Cardiol 2002;40:1414–1421. https://doi.org/10.1016/S0735-1097(02)02304-5 516. Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 2015;17:1294–1301. https://doi.org/10.1002/ejhf.347 517. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351: 2049–2057. https://doi.org/10.1056/NEJMoa042934 518. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007;115:1747–1753. https://doi. org/10.1161/CIRCULATIONAHA.106.644013 519. Abdul-Rahim AH, MacIsaac RL, Jhund PS, Petrie MC, Lees KR, McMurray JJ, et al. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: an analysis of the Digitalis Investigation Group (DIG) trial. Int J Cardiol 2016;209:310–316. https://doi.org/10.1016/j.ijcard.2016.02.074 520. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149–158. https://doi.org/10.1016/S0167-5273(01) 00600-3 521. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137–155. https://doi.org/10.1002/ejhf.1369 522. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150. https://doi.org/10. 1056/NEJMoa032423 523. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, et al. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Cardiac Fail 2007;13:769–773. https://doi.org/10.1016/j. cardfail.2007.06.723 524. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375:1221–1230. https://doi.org/10.1056/NEJMoa1608029 525. Rørth R, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace 2019;21:1203–1210. https://doi.org/10.1093/europace/euz114 526. Kilic A, Weiss ES, George TJ, Arnaoutakis GJ, Yuh DD, Shah AS, et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. Ann Thorac Surg 2012;93:699–704. https://doi.org/10.1016/j.athoracsur.2011.09.037 527. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016;9: e002560. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560 528. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am College Cardiol 2003;42:914–922. https://doi.org/10.1016/s0735-1097(03) 00856-8 529. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492 530. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–1461. https://doi.org/10.1056/NEJMoa2107038 531. Filippatos G, Butler J, Farmakis D, Zannad F, Pernille Ofstad A, Pedro Ferreira J, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 2022;146:676–686. https://doi.org/10.1161/ CIRCULATIONAHA.122.059785 532. Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286 533. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757–767. https://doi.org/10. 1016/S0140-6736(22)01429-5 534. Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al. Angiotensin– neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–1620. https://doi.org/10.1056/NEJMoa1908655 535. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392. https://doi.org/10.1056/NEJMoa1313731 536. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1: 211–217. https://doi.org/10.1016/S1388-9842(99)00039-2 537. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359: 2456–2467. https://doi.org/10.1056/NEJMoa0805450 538. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397–403. https://doi.org/10.1161/CIRCULATIONAHA. 106.628347 539. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. Eur Heart J 2021;42:4887–4890. https://doi.org/10.1093/eurheartj/ehab704 540. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RH, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; 139:2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130 541. Cosentino F, Cannon CP, Cherney DZ, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation 2020;142:2205–2215. https://doi.org/10.1161/CIRCULATIONAHA. 120.050255 542. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 1436–1446. https://doi.org/10.1056/NEJMoa2024816 543. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–127. https://doi.org/10.1056/NEJMoa2204233 544. Marso SP, Baeres FM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am College Cardiol 2020;75:1128–1141. https://doi.org/10.1016/j.jacc.2019. 12.063 545. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:189. https://doi.org/10. 1186/s12933-021-01366-8 546. Lam CS, Ramasundarahettige C, Branch KR, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose co-transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 2021;145:565–574. https://doi.org/10.1161/ CIRCULATIONAHA.121.057934 547. Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation 2020;142: 1205–1218. https://doi.org/10.1161/CIRCULATIONAHA.120.045888 548. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77. https://doi.org/10.1002/ejhf.657 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026